NHS (Neuberger Berman High Yield Strategies Fund) Revenue: $23.94 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NHS Neuberger Berman High Yield Strategies Fund Inc NHS
44 GF Score
Price $6.21
GF Value $7.23
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neuberger Berman High Yield Strategies Fund Revenue?

Neuberger Berman High Yield Strategies Fund NHS +0.08% 44 Revenue is $23.94 Mil as of Apr. 2026. GuruFocus rates NHS with a GF Score™ of 44/100 and a GF Value™ of $7.23 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Neuberger Berman High Yield Strategies Fund's revenue for the six months ended in Apr. 2026 was $5.43 Mil. Its revenue for the trailing twelve months (TTM) ended in Apr. 2026 was $23.94 Mil. Neuberger Berman High Yield Strategies Fund's Revenue per Share for the six months ended in Apr. 2026 was $0.13. Its Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $0.72.

Warning Sign:

Neuberger Berman High Yield Strategies Fund Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Neuberger Berman High Yield Strategies Fund was -2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 10 years, Neuberger Berman High Yield Strategies Fund's highest 3-Year average Revenue per Share Growth Rate was 9.30% per year. The lowest was -37.60% per year. And the median was -3.15% per year.


Neuberger Berman High Yield Strategies Fund  (AMEX:NHS) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Neuberger Berman High Yield Strategies Fund Revenue Related Terms


Neuberger Berman High Yield Strategies Fund Revenue Historical Data

* Premium members only.

The historical data trend for Neuberger Berman High Yield Strategies Fund's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuberger Berman High Yield Strategies Fund Revenue Chart

Neuberger Berman High Yield Strategies Fund Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.51 -30.38 9.74 41.75 23.45

Neuberger Berman High Yield Strategies Fund Semi-Annual Data
Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25 Apr26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.63 17.12 4.94 18.51 5.43

NHS vs NRO, TPVG, OPP: Revenue Comparison

For the Asset Management subindustry, Neuberger Berman High Yield Strategies Fund's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuberger Berman High Yield Strategies Fund Revenue vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Neuberger Berman High Yield Strategies Fund's Revenue distribution charts can be found below:

* The bar in red indicates where Neuberger Berman High Yield Strategies Fund's Revenue falls into.


NHS
44GF Score
Neuberger Berman High Yield Strategies Fund Inc NHS
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuberger Berman High Yield Strategies Fund Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Apr. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $23.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $23.94 Mil mean?
Neuberger Berman High Yield Strategies Fund (NHS) has a Revenue of $23.94 Mil as of Apr. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Neuberger Berman High Yield Strategies Fund and its competitors.
Is Neuberger Berman High Yield Strategies Fund's Revenue too high?
Neuberger Berman High Yield Strategies Fund's current Revenue is $23.94 Mil. Overall, Neuberger Berman High Yield Strategies Fund has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neuberger Berman High Yield Strategies Fund's Revenue compare to NRO and TPVG?
Neuberger Berman High Yield Strategies Fund's Revenue of $23.94 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for an Asset Management company?
A good Revenue depends on the Asset Management industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Neuberger Berman High Yield Strategies Fund and its competitors. Neuberger Berman High Yield Strategies Fund's current Revenue is $23.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuberger Berman High Yield Strategies Fund stock overvalued right now?
Based on GuruFocus' analysis, Neuberger Berman High Yield Strategies Fund (NHS) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.23, compared to a current price of $6.21 — trading 14.2% below its estimated fair value. The current Revenue is $23.94 Mil. Neuberger Berman High Yield Strategies Fund's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Neuberger Berman High Yield Strategies Fund (NHS), the current Revenue is $23.94 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuberger Berman High Yield Strategies Fund (NHS) Overvalued in 2026?

Based on GuruFocus' analysis, Neuberger Berman High Yield Strategies Fund stock appears to be undervalued. The current stock price of $6.21 is trading 14.2% below its estimated GF Value™ of $7.23. GuruFocus considers Neuberger Berman High Yield Strategies Fund to be Modestly Undervalued.

Key valuation signals for NHS:

  • Revenue: $23.94 Mil
  • GF Value™: $7.23 vs. price of $6.21 (14.2% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the NHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuberger Berman High Yield Strategies Fund Business Description

Address c/o Neuberger Berman Investment Advisers LLC, 1290 Avenue of the Americas, New York, NY, USA, 10104-0002
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
44GF Score

Get the complete analysis for NHS

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.21
Price
$7.23
GF Value